Research programme: TLR9 agonists - Pfizer

Drug Profile

Research programme: TLR9 agonists - Pfizer

Alternative Names: CpG 10104; CpG-ODN; TLR9 agonists research programme - Pfizer; Toll-like receptor 9 agonists - Pfizer

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Coley Pharmaceutical Group
  • Class
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Viral infections

Most Recent Events

  • 26 Dec 2017 Baylor College of Medicine plans a phase I trial with or without the CpG 10104 immunostimulant for Hookworm infections (in Gabonese volunteers) in January 2018 (NCT03373214)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Viral-infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top